Next Article in Journal
An Ultra-Sensitive Electrochemical Sensor for the Detection of Carcinogen Oxidative Stress 4-Nitroquinoline N-Oxide in Biologic Matrices Based on Hierarchical Spinel Structured NiCo2O4 and NiCo2S4; A Comparative Study
Next Article in Special Issue
Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers
Previous Article in Journal
Network of Palladium-Based Nanorings Synthesized by Liquid-Phase Reduction Using DMSO-H2O: In Situ Monitoring of Structure Formation and Drying Deformation by ASEM
Previous Article in Special Issue
Benzothiazolyl Ureas are Low Micromolar and Uncompetitive Inhibitors of 17β-HSD10 with Implications to Alzheimer’s Disease Treatment
Review

Combination Drug Therapy for the Management of Alzheimer’s Disease

1
Department of Pharmacy, BRAC University, Dhaka 1212, Bangladesh
2
Department of Pharmacy, Southeast University, Dhaka 1213, Bangladesh
3
Pharmakon Neuroscience Research Network, Dhaka 1207, Bangladesh
4
Research Unit, Induced Resistance and Plant Bioprotection, EA 4707, SFR Condorcet FR CNRS 3417, Faculty of Sciences, University of Reims Champagne-Ardenne, P.O. Box 1039, 51687 Reims CEDEX 2, France
5
Chrono-Environnement Laboratory, UMR CNRS 6249, Bourgogne Franche-Comté University, F-25030 Besançon, France
6
Department of Biochemistry, Faculty of Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia
7
King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia
8
Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia
9
Division of Drug Design and Medicinal Chemistry Research Lab, Department of Pharmaceutical Chemistry, Ahalia School of Pharmacy, Palakkad 678557, India
10
Department of Biology, College of Science, Princess Nourah bint Abdulrahman University, Riyadh 11474, Saudi Arabia
11
Department of Zoology, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia
12
Pharmacology Department, Faculty of Veterinary Medicine, Suez Canal University, Ismailia 41522, Egypt
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(9), 3272; https://doi.org/10.3390/ijms21093272
Received: 2 March 2020 / Revised: 19 March 2020 / Accepted: 19 March 2020 / Published: 5 May 2020
Alzheimer’s disease (AD) is the leading cause of dementia worldwide. Even though the number of AD patients is rapidly growing, there is no effective treatment for this neurodegenerative disorder. At present, implementation of effective treatment approaches for AD is vital to meet clinical needs. In AD research, priorities concern the development of disease-modifying therapeutic agents to be used in the early phases of AD and the optimization of the symptomatic treatments predominantly dedicated to the more advanced AD stages. Until now, available therapeutic agents for AD treatment only provide symptomatic treatment. Since AD pathogenesis is multifactorial, use of a multimodal therapeutic intervention addressing several molecular targets of AD-related pathological processes seems to be the most practical approach to modify the course of AD progression. It has been demonstrated through numerous studies, that the clinical efficacy of combination therapy (CT) is higher than that of monotherapy. In case of AD, CT is more effective, mostly when started early, at slowing the rate of cognitive impairment. In this review, we have covered the major studies regarding CT to combat AD pathogenesis. Moreover, we have also highlighted the safety, tolerability, and efficacy of CT in the treatment of AD. View Full-Text
Keywords: combination therapy; dementia; Alzheimer’s disease; multi-target-directed ligands combination therapy; dementia; Alzheimer’s disease; multi-target-directed ligands
Show Figures

Figure 1

MDPI and ACS Style

Kabir, M.T.; Uddin, M.S.; Mamun, A.A.; Jeandet, P.; Aleya, L.; Mansouri, R.A.; Ashraf, G.M.; Mathew, B.; Bin-Jumah, M.N.; Abdel-Daim, M.M. Combination Drug Therapy for the Management of Alzheimer’s Disease. Int. J. Mol. Sci. 2020, 21, 3272. https://doi.org/10.3390/ijms21093272

AMA Style

Kabir MT, Uddin MS, Mamun AA, Jeandet P, Aleya L, Mansouri RA, Ashraf GM, Mathew B, Bin-Jumah MN, Abdel-Daim MM. Combination Drug Therapy for the Management of Alzheimer’s Disease. International Journal of Molecular Sciences. 2020; 21(9):3272. https://doi.org/10.3390/ijms21093272

Chicago/Turabian Style

Kabir, Md. T., Md. S. Uddin, Abdullah A. Mamun, Philippe Jeandet, Lotfi Aleya, Rasha A. Mansouri, Ghulam M. Ashraf, Bijo Mathew, May N. Bin-Jumah, and Mohamed M. Abdel-Daim 2020. "Combination Drug Therapy for the Management of Alzheimer’s Disease" International Journal of Molecular Sciences 21, no. 9: 3272. https://doi.org/10.3390/ijms21093272

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop